Coherus Oncology (CHRS) Net Cash Flow Growth (5y) (2018 - 2026)
Coherus Oncology (CHRS) Net Cash Flow Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Coherus Oncology | 198.46 Mn | 31.41 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.93% |
| Dec 31, 2025 | -15.53% |
| Sep 30, 2025 | -29.72% |
| Jun 30, 2025 | 33.80% |
| Mar 31, 2025 | -36.63% |
| Dec 31, 2024 | 17.11% |
| Sep 30, 2024 | -25.05% |
| Jun 30, 2024 | -43.58% |
| Mar 31, 2024 | 75.98% |
| Dec 31, 2023 | 22.70% |
| Sep 30, 2023 | 17.65% |
| Jun 30, 2023 | 3.52% |
| Mar 31, 2023 | -1.10% |
| Dec 31, 2022 | -91.63% |
| Sep 30, 2022 | -28.89% |
| Jun 30, 2022 | 0.59% |
| Mar 31, 2022 | -264.85% |
| Dec 31, 2021 | 29.51% |
| Sep 30, 2021 | 20.14% |
| Jun 30, 2021 | 11.16% |